Clinigen gains approval to re-launch Telavancin pneumonia drug
18th Mar 2014 09:24
Clinigen Group said Tuesday that the European Commission (EC) had agreed to lift the Europe-wide suspension of marketing authorisation for Vibativ, its Telavancin treatment used to treat hospital-acquired pneumonia. The group said it consequently anticipates the commercial launch will begin in the
Read moreClinigen interim profits up, but shares fall sharply on broker downgrade
26th Feb 2014 13:05
Pharmaceuticals company Clinigen reported first half pre-tax profits of 9.6m pounds, up from 3.7m in 2012, but shares in the company were marked down sharply after a broker downgrade. Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) jumped 20% to £12.5m. Group revenu
Read moreWednesday broker round-up UPDATE
26th Feb 2014 08:54
Anglo Pacific: FinnCap cuts target price from 279p to 216p, downgrades to hold. Ashmore Group: UBS reduces target price from 405p to 355p, while leaving its buy recommendation unchanged. Jefferies cuts target price from 475p to 375p, while its buy recommendation is kept. Barclays lowers target pric
Read moreThursday broker round-up UPDATE
24th Oct 2013 09:25
Aquarius Platinum: Investec lowers target price from 48p to 42p and downgrades from hold to sell. ASOS: Citi increases target price from 5800p to 7000p reiterating its buy recommendation. BHP Billiton: Jefferies raises target price from 2350p to 2400p and keeps a buy recommendation. Clinigen: Inv
Read moreClinigen CEO sells a further 0.5m shares post placing
2nd Oct 2013 15:56
Pharmaceuticals and services business Clinigen said Wednesday that Peter George, its Chief Executive Officer, has sold a further 0.5m shares in addition to the 2.8m disposed of on Monday. The shares, which were all sold for 410p each, were part of the 8.7m placed with a number of directors on Mond
Read moreClinigen beats forecasts with profits growth across group
25th Sep 2013 10:41
Grabbing increased market share in clinical trial services helped power drugs and trial services provider Clinigen to impressive first full year results. The AIM company, which floated in September last year, lifted profits before tax and one-off costs 29% to £20.4m on revenues up 49% to £1226.m i
Read moreWednesday broker round-up UPDATE
25th Sep 2013 09:46
Amec: JP Morgan reduces target price from 1301p to 1243p and stays with its neutral rating. Amlin: UBS ups target price from 400p to 450p upgrading from neutral to buy. BAE Systems: UBS takes target price from 450p to 490p and maintains a buy recommendation. BHP Billiton: Alphavalue shifts target
Read moreGreggs Chairman shows faith after reporting reduced footfall
2nd May 2013 16:14
The Chairman of Greggs, the FTSE 250 baking group, on Thursday purchased 2,500 shares just a few days after the company warned investors profits are likely to come in at the lower end of the range of market expectations. Derek Netherton's £10,000 purchase saw him buy the shares at 399.9p each, and
Read moreClinigen Group acquires oncology support product from Novartis
26th Mar 2013 14:51
AIM-listed pharmaceutical products and services business Clinigen Group has acquired Cardioxane (dexrazoxane) from Novartis for 33m dollars in cash, payable in two tranches. Under the terms of the agreement, Clinigen will assume responsibility for manufacturing, registration, distribution, and com
Read moreTuesday broker round-up UPDATE
26th Mar 2013 07:41
Abbey Protection: Numis downgrades to hold with its target price at 120p. Aberdeen Asset Management: Bank of America raises target price from 425p to 455p keeping a neutral rating. JP Morgan moves target price from 498p to 532p, while its overweight rating remains unchanged. Exane BNP ups target pr
Read moreMonday broker round-up UPDATE
11th Mar 2013 07:23
Admiral Group: Berenberg ups target price from 1000p to 1060p, but still recommends selling. Amlin: Westhouse Securities raises target price from 440p to 455p, but downgrades from add to neutral. Anite Group: Invetsec downgrades from buy to hold with a target price of 157p. Aviva: Citigroup reduc
Read moreClinigen declares maiden divi after impressive stock market debut
27th Feb 2013 12:00
Clinigen, the speciality pharmaceuticals company which listed on the AIM market last autumn, saw shares surge on Wednesday after the firm reported a massive jump in first-half sales and declared a maiden dividend. Sales soared by 86% from £32.7m to £61.0m in the six months to December 31st, while u
Read moreWednesday broker round-up UPDATE
27th Feb 2013 08:11
: Panmure Gordon reduces target price from 2159p to 1742p and reiterates its hold recommendation. Antofagasta: JP Morgan cuts target price from 1485p to 1400p, while retaining its overweight rating. Barclays: Numis raises target price from 351p to 400p and upgrades to buy. BT Group: UBS moves tar
Read more